U.S. Machinery Stock News

Maximus stock overview Maximus (MMS) has drawn investor attention after a period of weaker share performance, with the stock showing negative returns over the past month and past 3 months. This has prompted closer scrutiny of its current valuation and fundamentals. See our latest analysis for Maximus. At a share price of $63.72, Maximus has seen a 30 day share price return of 18.32% and a 90 day share price return decline of 28.50%, while the 1 year total shareholder return sits at a decline...

Context for Agilysys (AGYS) investors Agilysys (AGYS) has drawn fresh attention after recent share price swings, with the stock showing mixed near term performance and a sharper decline over the past 3 months from a last close of $71.49. See our latest analysis for Agilysys. The recent pullback, including a 39% 3 month share price return decline and 38% year to date share price return decline from $71.49, contrasts with a 1 year total shareholder return of 6.4%, suggesting fading short term...

Moody's (MCO) is back in focus after quarterly earnings topped analyst expectations, with contributions from both its ratings and analytics divisions, along with higher full year earnings guidance and an increased quarterly dividend. See our latest analysis for Moody's. Despite a softer 30 day share price return of 5.91% and a 90 day share price return of 16.66%, Moody's 1 year total shareholder return of 12.47% and 3 year total shareholder return of 53.95% point to momentum that has built...

Noble recently participated in a project with Halliburton, ExxonMobil and the Wells Alliance Guyana team that achieved the first fully automated geological well placement with complete rig automation in offshore Guyana, integrating automated subsurface interpretation, well placement and real-time hydraulics. This milestone in Noble’s offshore operations highlights its role in advancing drilling automation, potentially reinforcing its positioning as a high-tech contractor in complex deepwater...

Fresh analyst commentary and Clorox (CLX) management remarks have pushed the stock back into focus as investors weigh cost inflation, trade down risks, currency headwinds, and a softer outlook for category growth. See our latest analysis for Clorox. At a share price of $104.89, Clorox has seen a 3.71% 1 day share price return and a 2.41% 7 day share price return. However, its 1 year total shareholder return of 21.39% and 5 year total shareholder return of 35.24% highlight fading longer term...

If you are looking at EPAM Systems and wondering whether the current share price reflects its true worth, the valuation picture is more nuanced than a quick glance at the chart suggests. The stock last closed at US$137.02, with a 0.6% move over the past week, a 6.1% decline over 30 days, and returns of 31.6% decline year to date and 5.5% decline over the past year, following even steeper 3-year and 5-year declines of 52.9% and 67.7% respectively. These moves have kept EPAM on the radar for...

AI is starting to reshape how healthcare is delivered, from spotting disease earlier to tailoring treatments and cutting wasted time in hospitals, just as energy driven inflation and higher yields keep pressure on costs worldwide. For investors, that mix of structural healthcare demand and AI driven efficiency tools offers exposure to a theme that is less tied to short term swings in consumer spending or manufacturing cycles. This article walks through 3 stocks from our Transformative AI...

What AbbVie’s Recent Share Performance Signals for Investors AbbVie (ABBV) has recently seen a one-month return of about a 10% decline and a past three-month return of roughly a 7% decline, even as its one-year total return stands at about 14%. See our latest analysis for AbbVie. At a share price of US$206.69, AbbVie’s recent share price return has been weak over the past month and quarter, while its multi year total shareholder returns remain clearly positive. This suggests momentum has...

Analyst coverage sparks fresh interest in Sezzle A new research note initiating coverage of Sezzle (SEZL) with an Outperform rating has pushed the stock into focus, as investors weigh that positive view against recent insider selling and earnings quality concerns. See our latest analysis for Sezzle. After the fresh Outperform rating, Sezzle’s recent 7.92% 1 day and 13.30% 7 day share price returns stand in contrast to its 6.34% 30 day share price decline, while a 125.16% 1 year total...

Recent analysis of past performance shows that Service Corporation International has not increased the number of funeral services performed over the last two years, while also reporting weaker free cash flow margins and a declining return on invested capital compared with sector expectations. This combination of stagnant service volumes and deteriorating profitability metrics suggests the company may be contending with demand constraints and limited high-return reinvestment...

Helmerich & Payne has completed the sale of Tulsa’s Utica Square retail center, with after-tax proceeds exceeding its US$100 million divestiture target and earmarked largely to retire the company’s remaining term loan as part of a balance sheet-focused portfolio review. The move marks a significant shift away from non-core real estate and frees up financial capacity that can be redeployed toward Helmerich & Payne’s core drilling and technology operations following its capital-intensive KCA...

Acuity (AYI) is back in focus after its second quarter 2026 earnings, where adjusted earnings per share came in ahead of expectations while revenue lagged forecasts, highlighting contrasting trends across its Lighting and Intelligent Spaces businesses. See our latest analysis for Acuity. The share price reaction has been mixed, with a 1 day share price return of 1.06% after earnings but a 90 day share price return representing a 28.55% decline. However, the 3 year total shareholder return of...

Xeris Biopharma Holdings (XERS) drew fresh investor attention after reporting fourth quarter 2025 earnings per share of US$0.06 on revenue of US$85.8 million, both above prior projections and supported by a reiteration of positive analyst views. See our latest analysis for Xeris Biopharma Holdings. At a share price of US$6.05, Xeris Biopharma’s recent 8.04% 7 day share price return and 4.13% 30 day share price return contrast with a 17.69% decline year to date. At the same time, the 37.19% 1...

Olin Corporation recently received an upgrade from Wells Fargo, with the firm citing expectations of stronger margins in its electrochemical operations supported by higher caustic soda prices and stable North American natural gas costs. This shift in analyst view highlights how Olin’s earnings outlook is increasingly being tied to both its cost position and evolving global chemical pricing shaped by geopolitical tensions. We’ll now examine how this margin-focused upgrade from Wells Fargo...

Assurant recently reported its ninth consecutive year of profitable growth, highlighted by strong Q4 2025 earnings, record mobile trade-in activity, and the launch of Assurant Home Warranty through a partnership with Compass International Holdings, expanding its reach in the real estate channel. These developments underline how Assurant’s diversified protection offerings and new distribution partnerships are reinforcing its position across connected devices, housing, and broader lifestyle...

Interactive Brokers Group (IBKR) has drawn fresh attention after reporting year over year gains in daily average revenue trades, client equity, and client accounts, alongside new crypto trading features for European and existing clients. See our latest analysis for Interactive Brokers Group. That product push into crypto comes as momentum in the shares has cooled recently, with a 7 day share price return of 7.74% and a 90 day share price return decline of 5.85%, while longer term total...

Recently, Remitly Global received a Buy rating from Freedom Capital Markets after reporting quarterly revenue growth and a shift from a net loss to a net profit, while insider selling activity increased. This mix of improving financial performance and negative insider sentiment, including Pankaj Sharma’s US$152,600 share sale under a Rule 10b5-1 plan, offers a contrasting view of internal and external confidence in the business. We’ll now examine how Remitly’s move to profitability,...

In early April 2026, The Cheesecake Factory Incorporated launched a new mobile app and offered Cheesecake Rewards members a free slice of any of its more than 30 cheesecake or layer cake flavors with any purchase for downloads and logins through April 30. This promotion not only encourages more guests to join and use the Cheesecake Rewards program, it also deepens digital engagement that could be important for repeat visits and data-driven marketing. We will now examine how this new...

In recent weeks, Tandem Diabetes Care has faced an extended losing streak and a reduction in its market value, amid investor concerns about its operating performance and financial health. Adding to this pressure, JPMorgan Chase & Co. cut its stake in the company by more than a third, underscoring shifting institutional confidence at a sensitive time. Now we’ll examine how weakening operating performance and JPMorgan’s reduced stake may influence Tandem Diabetes Care’s existing investment...

Recent Performance Snapshot Federal Signal (FSS) has attracted fresh attention after a strong 1 year total return of 55.23%, contrasting with a modest month gain of 0.31% and a 4.72% decline over the past 3 months. See our latest analysis for Federal Signal. The 1 year total shareholder return of 55.23% stands in contrast to the recent 4.72% 3 month share price decline and slightly negative year to date share price return, suggesting that momentum has cooled following a strong multi year...

How Four Corners Property Trust Stock Has Been Performing Four Corners Property Trust (FCPT) has drawn attention after recent trading, with the stock closing at $23.44 and showing mixed return patterns over the past week, month and past 3 months. Over the past day, FCPT recorded a 1.31% decline, with a 1.97% decline across the last week and an 8.72% decline over the past month. The past 3 months have been relatively flat, with a total return of 0.21%. Looking at a slightly longer horizon, the...

In early April 2026, Intellia Therapeutics received an upgrade from Jones Trading after the FDA lifted clinical holds on its MAGNITUDE and MAGNITUDE-2 ATTR trials, restoring regulatory clarity following a patient death deemed likely unrelated to the company’s treatment. This renewed regulatory confidence, alongside expectations for key HAELO Phase 3 data, highlights how safety assessments can critically reshape perceptions of Intellia’s CRISPR pipeline and commercial pathway. With clinical...

In early April 2026, Prestige Consumer Healthcare faced pressure after regulatory scrutiny, including FTC concerns over industry consolidation and a federal healthcare fraud crackdown, weighed on sentiment around its over-the-counter product portfolio. Beyond the immediate regulatory overhang, the episode highlights how sector-wide oversight can quickly reshape market perceptions of risk around even established healthcare brands. Against this backdrop of intensified regulatory attention,...

Why the Cox Business Contact Center launch matters for RingCentral (RNG) Cox Business has launched Cox Business Contact Center with RingCentral, built on RingCX. The offering puts AI-first contact center tools such as virtual agents, omni-channel engagement, and CRM integrations in front of a broad base of business customers. See our latest analysis for RingCentral. RingCentral's recent news sits against a backdrop where the share price is US$38.08, with a 32.22% 90 day share price return and...